Synchroneuron Secures $20,000,000 Series B Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    130 Tobey Garden Street Duxbury, MA 02332 USA
  • Company Description
    Synchroneuron Inc., a Waltham, Mass.-based biopharmaceutical company that develops new therapies for tardive dyskinesia (TD) and other related movement disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    This funding supports the continued development of SNC-102, a new formulation of acamprosate calcium currently being studied in a Phase 2 trial to treat moderate-to-severe tardive dyskinesia (TD).
  • M&A Terms
  • Venture Investor

Trending on Xconomy